Free Trial

Brokerages Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) PT at $167.36

Axsome Therapeutics logo with Medical background
Remove Ads

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) have been given a consensus recommendation of "Buy" by the fifteen brokerages that are currently covering the stock, MarketBeat.com reports. Fifteen investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $167.36.

Several equities research analysts have commented on AXSM shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $153.00 target price on shares of Axsome Therapeutics in a research note on Monday, March 3rd. William Blair reaffirmed an "outperform" rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Truist Financial upped their target price on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Deutsche Bank Aktiengesellschaft began coverage on shares of Axsome Therapeutics in a research report on Tuesday, February 11th. They set a "buy" rating and a $176.00 price objective for the company. Finally, Wells Fargo & Company increased their price objective on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th.

Get Our Latest Analysis on Axsome Therapeutics

Axsome Therapeutics Trading Down 1.8 %

NASDAQ AXSM traded down $2.24 during trading hours on Thursday, hitting $122.17. The company's stock had a trading volume of 509,828 shares, compared to its average volume of 1,028,153. The stock has a fifty day moving average of $108.78 and a 200 day moving average of $97.76. Axsome Therapeutics has a twelve month low of $64.11 and a twelve month high of $139.13. The firm has a market capitalization of $5.96 billion, a P/E ratio of -20.40 and a beta of 1.00. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22.

Remove Ads

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The firm had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million. Equities research analysts forecast that Axsome Therapeutics will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the sale, the chief financial officer now owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 22.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Axsome Therapeutics

A number of large investors have recently added to or reduced their stakes in AXSM. Boxer Capital Management LLC acquired a new stake in Axsome Therapeutics in the fourth quarter valued at $39,767,000. Lazard Asset Management LLC lifted its stake in Axsome Therapeutics by 525.7% in the fourth quarter. Lazard Asset Management LLC now owns 537,669 shares of the company's stock valued at $45,492,000 after acquiring an additional 451,737 shares during the last quarter. Norges Bank acquired a new stake in Axsome Therapeutics in the fourth quarter valued at $34,100,000. BVF Inc. IL lifted its stake in Axsome Therapeutics by 32.7% in the fourth quarter. BVF Inc. IL now owns 1,388,064 shares of the company's stock valued at $117,444,000 after acquiring an additional 342,064 shares during the last quarter. Finally, Iron Triangle Partners LP acquired a new stake in Axsome Therapeutics in the third quarter valued at $22,671,000. Institutional investors and hedge funds own 81.49% of the company's stock.

Axsome Therapeutics Company Profile

(Get Free Report

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

See Also

Analyst Recommendations for Axsome Therapeutics (NASDAQ:AXSM)

Should You Invest $1,000 in Axsome Therapeutics Right Now?

Before you consider Axsome Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.

While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads